X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

CleveXel Pharma partners with Guilin Pharmaceutical to develop two new anti-malarial products

Yuvraj_pawp by Yuvraj_pawp
4th September 2014
in Research & Development

CleveXel Pharma today announces that the company has entered into a new partnering agreement with Guilin Pharmaceutical, a Chinese company located in Shanghai, regarding the development of two new products.

Guilin Pharmaceutical, a member of Fosun Pharma, is the first Chinese pharmaceutical manufacturer approved by the World Health Organization. It is also China’s largest artemisinin based anti-malarial drug producer. Artemisinin is an active substance derived from the traditional Chinese pharmacopeia.

 

This new work complements two other projects between the partners, which started in 2013. The purpose of the latest venture is to increase anti-malarial manufacturing across three active units. It includes an adult and pediatric formulation. This field is competitive and highly time-sensitive. 

 

The risks and costs of development will be split between each company, along with the expected commercial success and associated royalties. As compensation for the development work undertaken by CleveXel Pharma, Guilin Pharmaceutical will pay development milestones to CleveXel Pharma and a royalty based on Guilin Pharmaceutical’s net sales.

 

Guilin Pharmaceutical only selects the most efficient partners in order to optimize its worldwide reach and market access. CleveXel Pharma is a highly experienced pharmaceutical developer that conforms fully with cGMP’s and global regulatory compliance. “We are very happy to collaborate with CleveXel Pharma and to gain access to its development expertise,” said Zhemin Yu, chairman of Guilin Pharmaceutical. 

 

This relationship perfectly reflects the aims of the CleveXel Pharma business model; the company has developed a deep understanding of Chinese partners and enjoys a long track record of success in the region. This new project reinforces their lead as a ‘go-to’ partner for Chinese operators.

 

Technological project portfolios represent one fifth of CleveXel Pharma’s current activity. “Clevexel Pharma will use its innovative formulation development, including process optimization and industrial transfer, on these new projects. We are delighted to further collaborate with Guilin Pharmaceutical, which leads the way in anti-malarials for the Chinese and African markets,” said Christian Bloy, CEO of CleveXel Pharma. 

About CleveXel Pharma

CleveXel Pharma is a key pharmaceutical player in France. It has a 20 year history in pharma development. By operating as an investor it is introducing a new business model to the industry. CleveXel Pharma has an exceptional track record in the development of innovative therapies. The company has highly-trained and qualified teams, particularly in the field of the central nervous system, neurodegenerative diseases and oncology. 

 

CleveXel Pharma aims to bridge the gap between the worlds of academia and biotech and big pharma. Unlike CROs, this model is based on partnership and collaboration. CleveXel Pharma provides technical and financial value to projects by managing preclinical and clinical development for its partners. CleveXel Pharma can audit the potential of a given project and then catalyze the ongoing development to increase both the project value and its appeal to the pharmaceutical industry. Between the ‘proof of concept’ on animals and the ‘proof of concept’ on humans, CleveXel Pharma significantly reduces early capital needs by securing and consolidating the major milestones of the project. 

 

CleveXel Pharma can enhance and ensure the attractiveness of the projects to attract other partners, facilitate fundraising and maximize their marketing potential.

 

Innovation and operational excellence qualifies the ethical service provided by the highly regulated technology of CleveXel Pharma. To date, CleveXel Pharma is engaged in five projects and continues to actively expand its portfolio in the areas of oncology, CNS and immuno-inflammation.

http://www.clevexelpharma.com/ 
http://fr.viadeo.com/fr/company/clevexel-pharma 
http://www.linkedin.com/company/clevexel-pharma

About Guilin Pharmaceutical Co., Ltd

Established in the 1950’s, Guilin Pharma is a professional pharmaceutical enterprise specialized in researching, manufacturing and marketing pharmaceutical products. The company produces more than 200 chemical medicines in different dosage forms such as tablets, capsules and injections. As the first Chinese pharmaceutical manufacturer approved by the World Health Organization, Guilin Pharma is also China’s largest artemisinin based anti-malarial drug producer. It has the world’s most integrated artemisinin industry value chain.

Guilin Pharma products have been registered and marketed in more than 30 countries. As a World Health Organization approved anti-malarial producer, Guilin Pharma has supplied over 200 million oral treatments of its artemisinin based anti-malaria drugs to the world malaria campaign. Guilin Pharma also works with international NGOs, academic institutions and the local malaria control programs on training projects to improve the medical skills of local medical staff, to help reduce mortality in African children.

 

Guilin Pharma believes in a management philosophy of ‘quality comes first’. It continuously improves its production processes with international Good Manufacturing Practices standards to supply high quality pharmaceuticals. 

 

For more information: http://www.ala.com/article.php?id=445 

Mark Tidmarsh
//mark@ala.com/” target=”_blank” style=”margin: 0px; padding: 0px; border: 0px; outline: 0px; color: rgb(17, 85, 204); background: transparent;”>mark@ala.com 
ANDREW LLOYD & ASSOCIATES
http://www.ala.com

https://twitter.com/ALA_Group
Tel UK:      +44 1273 675100
Tel France: +33 1 56 54 07 00       
Tel US:      +1 617 517 0146

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION

Previous Post

CleveXel Pharma, Guilin Pharmaceutical partner to speed up development of anti-malarial products

Next Post

Bayer seeks marketing authorisation of aflibercept solution for injection in Japan

Related Posts

News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
Report Indicates UK £62bn Behind In Global R&D Investment
News

Report Indicates UK £62bn Behind In Global R&D Investment

3rd November 2022
News

Once More, M&As In Biotechechnology Industry Are Thriving

2nd November 2022
DNA
News

Ancient Viral DNA Guards Against Infections In Human Genome

31st October 2022
News

Omicron Subvariants Withstand Essential Antibody Treatments

31st October 2022
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
News

Research And Development In UK Falls Behind Other Nations

28th October 2022
Next Post

Bayer seeks marketing authorisation of aflibercept solution for injection in Japan

Latest News

FDA Approvals

NHS Acquires Potentially Lifesaving Breast Cancer Medication

9th November 2022
Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In